MoleculeMind Secures Over $100 Million in Series A Funding to Advance AI-Driven Protein Design Platform

MoleculeMind, an industry-leading AI protein design platform company, has completed its Series A financing round, raising a cumulative total of over $100 million. This round saw participation from investors including Blue Bridge Capital, Pudong Venture Capital, COFCO Emerging Industries Fund, Oriental Fortune Capital, Fosun RZ Capital, Guofang Ventures, Sepax Technologies (688758), Infinity Group, Caixin Capital, and Zhengding. Existing shareholders such as Cathay Biotech (688065) and Xinhang Capital also increased their investments. The diverse investor lineup fully reflects the deep consensus and joint commitment to MoleculeMind from financial investment institutions, industrial capital, and strategic guidance capital.

Amidst the capital market’s clamor for ultimate “certainty” and AI for Science (AI4S) entering deep waters, this financing round sends a clear signal: global competition in the AI protein sector has comprehensively shifted from “single-model benchmarking” in laboratories to an industrial-level contest focused on “solving real industry pain points and achieving closed-loop commercialization.” In this reshuffling, MoleculeMind is establishing its rare status as the definer of global AI protein industry infrastructure, leveraging world-leading foundational technologies, verifiable industrial-grade achievements, and rare cross-sector capital consensus.

Xu Jinbo is the inventor of RaptorX-Contact, the world’s first effective AI algorithm for protein structure prediction, and a world-class scientist hailed as the “founder of AI-driven protein folding.” Following the first paradigm shift in protein structure prediction, he is now leading the MoleculeMind team to drive another transformation: propelling the development of biomacromolecules from an era of “random trial-and-error” into a deterministic age of “programmable bioengineering.”